Micron Technology: The Market May Be Wrong
Micron is expected to benefit from AI-driven demand and strategic investments in cutting-edge technologies. Read why ...
OpenAI expands footprint as it leases Manhattan office space: report
Microsoft-backed OpenAI is expanding its geographic footprint as it leases a 90,000-square foot office space in New York City ...
Seeking Alpha24m
HODL: Best Current Spot Bitcoin ETF
Bitcoin's long-term value is driven by the unstable nature of modern monetary policy and its potential as a hedge against ...
What To Do After Futu Holdings Stock Soared
Discover why Futu Holdings' stock surged 107.7% in the last month, driven by strong Q2 results and China's unexpected ...
Greif: Attractive Enough To Be Bullish About
Despite mixed financial performance, Greif, Inc. remains a buy due to growth potential, strategic acquisitions, and ...
Moctezuma's Capital Allocation Is Great, And The Stock Is A Buy At These Prices
Moctezuma does not have significant uses for its profits, and returns most of the capital to shareholders. The company’s ...
Generali: Time To Take Profits Despite Its High Dividend Yield
Analysis of Generali's financial performance in H1 2024, including challenges in the P&C segment and potential for investors ...
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Discover Cardiff Oncology's promising results with Onvansertib for RAS-mutated colorectal cancer, potentially leading to major market growth. Click here to read.